NICE recommends Alexion’s asfotase alfa across England
Therapy involves patients with paediatric-onset hypophosphatasia – a rare bone disease
Read Moreby John Pinching | Jan 27, 2023 | News | 0
Therapy involves patients with paediatric-onset hypophosphatasia – a rare bone disease
Read Moreby Lucy Parsons | Jul 26, 2021 | News | 0
European drug regulator has recommended Ultomiris for use in children and adolescents with PNH
Read Moreby Lucy Parsons | Jul 14, 2021 | News | 0
UK approval of the acquisition comes just a week after the merger scored clearance in the EU
Read Moreby Lucy Parsons | Jul 6, 2021 | News | 0
Clearance in the UK is still pending and remains a requirement to complete the proposed deal
Read Moreby Selina McKee | May 20, 2021 | News | 0
Around 270 people with PNH and 160 people with aHUS will be eligible for the new treatment
Read Moreby Lucy Parsons | May 11, 2021 | News | 0
Committee also accepted Braftovi combination, Ledaga and Zejula for use by NHS Scotland in May decisions
Read Moreby Lucy Parsons | Apr 16, 2021 | News | 0
C5 complement inhibitor approved to treat PNH in adult patients with haemolysis
Read Moreby Selina McKee | Apr 6, 2021 | News | 0
Funding backed for reversal of gastrointestinal bleeds but not for intracranial haemorrhage
Read Moreby Anna Smith | Aug 28, 2019 | News | 0
At 48 weeks, 98% of patients treated with the drug were relapse free compared to 63% of patients receiving placebo.
Read Moreby Selina McKee | Jul 4, 2019 | News | 0
The decision allows use of the drug in patients with haemolysis with clinical symptoms indicative of high disease activity
Read Moreby Selina McKee | Apr 11, 2018 | News | 0
Alexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million.
Read Moreby Selina McKee | Mar 16, 2018 | News | 0
Alexion is gearing up to file its experimental therapy for paroxysmal nocturnal hemoglobinuria (PNH) with regulators on both sides of the Altantic following the success of a late-stage clinical trial.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
